Oncology Small Molecule Drugs Market
Oncology Small Molecule Drugs Market Analysis, By Drug Class (Chemotherapy, Immunomodulating, Targeted Therapy Drugs), By Indication (NSCLC, Renal Cell Carcinoma, Breast Cancer), By RoA (Oral, Injectable), By Distribution Channel, By Region - Global Insights to 2032
Analysis of Oncology Small Molecule Drugs market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Oncology Small Molecule Drugs Market Outlook (2022-2032)
The global oncology small molecule drugs market has reached a valuation of US$ 79 billion in 2022 and is forecasted to expand at a CAGR of 5.5% to climb to a market size of US$ 135.4 billion by 2032.
North America leads the global oncology small molecule drugs market and is expected to contribute more than 50% share over the assessment period (2022-2032).
Report Attributes |
Details |
|---|---|
|
Oncology Small Molecule Drugs Market Size (2021A) |
US$ 74.3 Billion |
|
Estimated Market Value (2022E) |
US$ 79 Billion |
|
Forecasted Market Value (2032F) |
US$ 135.4 Billion |
|
Global Market Growth Rate (2022-2032) |
5.5% CAGR |
|
North America Market Share (2021) |
~48.2% |
|
East Asia Market Growth Rate (2022-2032) |
~5.2% CAGR |
|
United States Market Growth Rate (2022-2032) |
~5.5% CAGR |
|
Market Share of Top 5 Companies |
~26.7% |
|
Key Companies Profiled |
|
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Analysis of Sales of Oncology Small Molecule Drugs (2017-2021) Vs. Market Estimations (2022-2032)
Over the past few decades, technological advancements in cancer treatment have captured the attention of the global healthcare community. Since it is the second-leading cause of death worldwide, cancer treatment has traditionally been prioritized by government, non-government, and private organizations.
The development of techniques to test chemicals using transplantable tumors led to the beginning of the use of chemotherapy to treat cancer at the turn of the 20th century. Epigenetic and environmental variables play a significant role in the development of tumors, in addition to genetic changes in cancer cells.
Traditional medicines have proven successful in treating cancer; however, because of their non-specific activity on both normal and malignant cells, they frequently produced negative side effects. As a result, small molecule inhibitor-based tailored therapeutic approaches are being thoroughly researched.
The inevitable need for targeted drug development to cure fatal diseases such as cancer has encouraged the pharmaceutical industry to come up with various treatment solutions, which has created opportunistic growth prospects for the pharmaceutical market at a compound annual growth rate of 5.5% from 2022 to 2032.
The development of small molecule medicines for cancer therapies in present times is revolutionary and has completely changed the landscape of cancer therapy. Small molecule medications have made such significant advancements that they have surpassed all other consequential advancements in the field of cancer therapeutics, including immune cells and radiation therapy.
The popularity of small molecule cancer medications is steadily rising due to factors such as better overall results, minimal drawbacks, earlier treatment initiation, small drug sizes, etc. Small molecule cancer medications have all of the aforementioned important advantages over other traditional immunotherapies, and the identified clinical trial landscape for them concludes their significance and demand to be thought of as standard therapy.
Owing to these beneficial factors, the oncology small molecule drugs market is expected to offer an absolute $ opportunity of US$ 61.1 billion between 2022 and 2032.
- Short Term (2022-2025): Adoption of small molecule drugs for the treatment of cancer has significantly driven the global market as these drugs notably reduced the mortality rate by overcoming limitations of conventional cancer therapies such as radiation therapy and chemotherapy.
- Medium Term (2025-2028): Improved healthcare services and increment in per-capita spending on healthcare in underdeveloped regions will further contribute to an increase in the sales of small molecule drugs. Regions such as East Asia and MEA will witness incremental opportunistic growth.
- Long Term (2028-2032): Small molecule drug demand is forecasted to rise globally due to rigorous research and development in the field of cancer. Personalized targeted drug production and new product launches, along with regulatory approvals, will drive the growth of the market.
Between 2017 and 2021, consumption of oncology small molecule drugs increased at a CAGR of 5.4%. As per the study by Fact.MR, a market research and competitive intelligence provider, the market is projected to progress at 5.5% CAGR between 2022 and 2032.
Market share analysis of oncology small molecule drugs based on drug class, and region. Targeted therapy drugs occupy 51.2% market share by drug class in 2022.
What is the Scenario for the Demand for Oncology Small Molecule Drugs?
“New & Effective Drug Launches and Vigorous Product Pipelines”
The popularity of small molecule cancer medications is steadily rising among patients due to an increase in the occurrence of cancer cases. Small molecule drugs are recorded to have better overall results, with minimal drawbacks, earlier treatment initiation, small drug sizes, etc.
Small molecule cancer medications have all of the aforesaid important advantages over other traditional immunotherapies, and recognized clinical trials support their significance and need to be thought of as standard therapy.
There are more than 2,500 small molecule cancer medications undergoing clinical studies at the moment. A majority of medications are in the preclinical stage, which is followed by Phase-I clinical trials. Currently, there are more than 200 small molecule cancer medications.
Modern technology is being incorporated by manufacturers to lower cancer risks and improve its therapy. Additionally, to lower the death rate, governments are funding the development of sophisticated cancer drugs that are affordable and widely accessible.
“High Drug Manufacturing & Purchasing Costs Affecting Both Producers and Consumers”
The small molecule oncology medication industry has a highly competitive and consolidated vendor landscape. Because oncology small molecule medications are a relatively new class of cancer therapeutics, they require a high level of clinical competence and are expensive; hence, only a few major pharmaceutical companies produce these kinds of drugs.
To conduct these delicate studies, pharmaceutical companies need contemporary, well-equipped research laboratories. Another constraint on producers is the delay in regulatory and drug federation approval of products followed by successful clinical trials. Increased medicine manufacturing and launch costs will have an immediate impact on the prices of final products. Higher medicine prices may distract the attention of the world's middle-class population, which could eventually result in manufacturers’ revenue and resource loss.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
Will Progression of Healthcare Sector in the U.S. Drive High Demand for Oncology Small Molecule Drugs?
- According to the American Cancer Society, 1.8 million new instances of cancer will be diagnosed nationwide in 2020, with 606,520 deaths.
Pharmaceutical corporations are seeking quicker approvals of their potential therapeutic candidates. The FDA's subsequent clearance of cancer medications has opened up new markets for oncology-specific medications in the nation. Manufacturers are also concentrating on technological developments in the medication development cycle, which will maximize the discovery of novel and efficient medicines.
With a high percentage of cancer patients seeking treatment and favorable reimbursement policies provided by insurance companies, North America is anticipated to generate US$ 38.1 billion in revenue in 2022.
Why is the East Asia Oncology Small Molecule Drug Market Flourishing?
China and Japan are two of the biggest East Asian nations, and together, they contribute to a significant market share in both technology and healthcare. China is second in the global market, accounting for nearly 30% of all lung cancer cases, 40% of stomach cancer cases, and 50% of liver cancer cases worldwide, in its oncology market alone. Furthermore, China has a death rate from cancer that is 40% higher than the U.S. average.
- 'Elunate', a colon cancer treatment, just gained China's first full approval of a drug developed following contemporary clinical studies (fruquintinib).
This will promote the growth of the nation's small molecule oncology drugs market. East Asia is expected to generate US$ 16.7 billion in revenue in 2032.
Category-wise Insights
Why is Oral Route of Administration Most Popular for Drug Intake?
The oral route of administration is widely preferred by patients as oral drugs are easy to consume and monitor and patients do not require any specialized training to administer the drug. Besides, they are economical as it does not require extra expenditure spending.
Owing to their several advantages, oral targeted treatments are most generously being utilised to treat cancer. They function by obstructing particular chemicals or processes that contribute to the formation of tumors. Currently, targeted drug delivery is proving to be a successful strategy for oral therapeutic drug delivery.
Why are Drugs for Targeted Therapy Becoming a Dominant Drug Class?
Since targeted therapy can help prevent cancer cells from reproducing, it is becoming an increasingly important type of cancer treatment. Targeted treatment medications are anticipated to account for 50% of global sales, according to Fact.MR.
Oncology small molecule medications that target a particular genetic mutation known as NTRK fusion, such as larotrectinib (Vitrakvi), are steadily receiving FDA approvals, which will boost their market share.
A growing number of small-molecule targeted medicines have been created for the treatment of malignancies.
- The U.S. Food and Drug Administration (FDA) approved the first tyrosine kinase inhibitor 'imatinib' for market sales in 2001.
Targeted medications have emerged and proliferated quickly in the market owing to their several benefits.
Competitive Landscape
Several well-known market players are adopting novel strategies, including ground-breaking marketing strategies, technical developments, mergers, and acquisitions.
Market players such as Novartis AG, Pfizer Inc., Amgen Plc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, AbbVie Inc., Bayer AG, Incyte Corporation, Celgene Corporation, AstraZeneca Plc., Exelixis Inc., and Millennium Pharmaceuticals Inc. (Takeda) are utilising sustainable technology and optimization strategies for a variety of end users.
Additionally, manufacturers’ primary marketing plans are based on their expertise in planning, coming up with, and delivering the best solutions. Manufacturers in the market also want to expand their product distribution into developing and low-income nations.
- The U.S. Food and Drug Administration granted Novartis AG's Lu-PSMA-617, an investigational radiation therapy for advanced castration-resistant prostate cancer, the classification of 'breakthrough therapy', in June 2021.
- Sanofi and Synthorx, Inc., a clinical-stage biotechnology firm devoted to extending and enhancing the lives of people with cancer and autoimmune illnesses, entered into a formal deal worth roughly US$ 2.5 billion in December 2019.
Segmentation of Oncology Small Molecule Drugs Industry Research
-
By Drug Class :
- Chemotherapy Drugs
- Alkylating Agents
- Antimetabolites
- Other Drugs
- Immunomodulating Drugs
- Targeted Therapy Drugs
- Proteasome Inhibitors
- Tyrosine Kinase Inhibitors
- mTOR Inhibitors
- Others
- Hormonal Therapy
- Chemotherapy Drugs
-
By Indication :
- NSCLC
- Renal Cell Carcinoma
- Breast Cancer
- Prostate Cancer
- Multiple Myeloma
- Melanoma
- Lymphoma
- Leukemia
- Others
-
By RoA :
- Oral
- Injectable
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Clinics
- Online Pharmacies
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & ASEAN
- Oceania
- MEA
Table of Content
1. Oncology Small Molecule Drugs Market - Executive Summary 2. Market Overview 2.1. Market Definition and Introduction 2.2. Market Taxonomy/ Research Scope 3. Market Background and Foundation Data 3.1. Global Cancer Patients Analysis 3.2. Oncology Drugs Market Outlook 3.3. Oncology Small Molecule Drugs Indication Analysis 3.3.1. By Region 3.3.2. By Key companies 3.4. Growth & Development Pattern in Oncology Small Molecule Drugs Market 3.5. Oncology Small Molecule Drugs Opportunity Assessment 3.5.1. Total Available Market (US$ Billion) 3.5.2. Serviceable Addressable Market (US$ Billion) 3.5.3. Serviceable Obtainable Market (US$ Billion) 3.6. Market White Space Assessment 3.7. Market Dynamics 3.7.1. Market Growth Drivers 3.7.2. Market Restraints 3.7.3. Market Opportunity 3.7.4. Market Trends 3.8. Forecast and Macro-Economic Factors – Relevance and Impact 3.9. PESTLE Analysis 3.10. Porter’s Five Force Analysis 3.11. Investment Feasibility Analysis 3.12. Key Success Factors 4. Global Oncology Small Molecule Drugs Market Value (US$ Billion) Analysis and Forecast 4.1. Historical Market Value (US$ Billion) Analysis, 2017-2021 4.2. Current and Future Market Value (US$ Billion) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Oncology Small Molecule Drugs Market Analysis and Forecast, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size (US$ Billion) Analysis By Drug Class, 2017-2021 5.3. Current and Future Market Size (US$ Billion) Analysis Forecast By Drug Class, 2022-2032 5.3.1. Chemotherapy Drugs 5.3.1.1. Alkylating Agents 5.3.1.2. Antimetabolites 5.3.1.3. Other Drugs 5.3.2. Immunomodulating Drugs 5.3.3. Targeted Therapy Drugs 5.3.3.1. Proteasome Inhibitors 5.3.3.2. Tyrosine Kinase Inhibitors 5.3.3.3. mTOR Inhibitors 5.3.3.4. Others 5.3.4. Hormonal Therapy 5.4. Market Attractiveness Analysis By Drug Class 6. Global Oncology Small Molecule Drugs Market Analysis and Forecast, By Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size (US$ Billion) Analysis By Indication, 2017-2021 6.3. Current and Future Market Size (US$ Billion) Analysis Forecast By Indication, 2022-2032 6.3.1. NSCLC 6.3.2. Renal Cell Carcinoma 6.3.3. Breast Cancer 6.3.4. Prostate Cancer 6.3.5. Multiple Myeloma 6.3.6. Melanoma 6.3.7. Lymphoma 6.3.8. Leukemia 6.3.9. Others 6.4. Market Attractiveness Analysis By Indication 7. Global Oncology Small Molecule Drugs Market Analysis and Forecast, By Route of Administration 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Billion) Analysis By Route of Administration, 2017-2021 7.3. Current and Future Market Size (US$ Billion) Analysis Forecast By Route of Administration, 2022-2032 7.3.1. Oral 7.3.2. Injectable 7.4. Market Attractiveness Analysis By Route of Administration 8. Global Oncology Small Molecule Drugs Market Analysis and Forecast, By Distribution Channel 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Billion) Analysis By Distribution Channel, 2017-2021 8.3. Current and Future Market Size (US$ Billion) Analysis Forecast By Distribution Channel, 2022-2032 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.3.3. Specialty Clinics 8.3.4. Online Pharmacies 8.4. Market Attractiveness Analysis By Distribution Channel 9. Global Oncology Small Molecule Drugs Market Analysis and Forecast, By Region 9.1. Introduction 9.2. Historical Market Size (US$ Billion) Analysis By Region, 2017-2021 9.3. Current Market Size (US$ Billion) Analysis Forecast By Region, 2022-2032 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. East Asia 9.3.5. South Asia & ASEAN 9.3.6. Oceania 9.3.7. Middle East & Africa 9.4. Market Attractiveness Analysis By Region 10. North America Oncology Small Molecule Drugs Market Analysis and Forecast 10.1. Introduction / Key Findings 10.2. Pricing Analysis 10.3. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2017-2021 10.4. Market Size (US$ Billion) Forecast By Market Taxonomy, 2022 - 2032 10.4.1. By Country 10.4.1.1. U.S. 10.4.1.2. Canada 10.4.2. By Drug Class 10.4.3. By Indication 10.4.4. By Route of Administration 10.4.5. By Distribution Channel 10.5. Market Attractiveness Analysis 10.5.1. By Country 10.5.2. By Drug Class 10.5.3. By Indication 10.5.4. By Route of Administration 10.5.5. By Distribution Channel 11. Latin America Oncology Small Molecule Drugs Market Analysis and Forecast 11.1. Introduction / Key Findings 11.2. Pricing Analysis 11.3. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2017-2021 11.4. Market Size (US$ Billion) Forecast By Market Taxonomy, 2022 - 2032 11.4.1. By Country 11.4.1.1. Brazil 11.4.1.2. Mexico 11.4.1.3. Argentina 11.4.1.4. Rest of Latin America 11.4.2. By Drug Class 11.4.3. By Indication 11.4.4. By Route of Administration 11.4.5. By Distribution Channel 11.5. Market Attractiveness Analysis 11.5.1. By Country 11.5.2. By Drug Class 11.5.3. By Indication 11.5.4. By Route of Administration 11.5.5. By Distribution Channel 12. Europe Oncology Small Molecule Drugs Market Analysis and Forecast 12.1. Introduction / Key Findings 12.2. Pricing Analysis 12.3. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2017-2021 12.4. Market Size (US$ Billion) Forecast By Market Taxonomy, 2022 - 2032 12.4.1. By Country 12.4.1.1. Germany 12.4.1.2. France 12.4.1.3. Italy 12.4.1.4. Spain 12.4.1.5. U.K. 12.4.1.6. BENELUX 12.4.1.7. Russia 12.4.1.8. Rest of Europe 12.4.2. By Drug Class 12.4.3. By Indication 12.4.4. By Route of Administration 12.4.5. By Distribution Channel 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Drug Class 12.5.3. By Indication 12.5.4. By Route of Administration 12.5.5. By Distribution Channel 13. East Asia Oncology Small Molecule Drugs Market Analysis and Forecast 13.1. Introduction / Key Findings 13.2. Pricing Analysis 13.3. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2017-2021 13.4. Market Size (US$ Billion) Forecast By Market Taxonomy, 2022 - 2032 13.4.1. By Country 13.4.1.1. China 13.4.1.2. Japan 13.4.1.3. South Korea 13.4.2. By Drug Class 13.4.3. By Indication 13.4.4. By Route of Administration 13.4.5. By Distribution Channel 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Drug Class 13.5.3. By Indication 13.5.4. By Route of Administration 13.5.5. By Distribution Channel 14. South Asia & ASEAN Oncology Small Molecule Drugs Market Analysis and Forecast 14.1. Introduction / Key Findings 14.2. Pricing Analysis 14.3. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2017-2021 14.4. Market Size (US$ Billion) Forecast By Market Taxonomy, 2022 - 2032 14.4.1. By Country 14.4.1.1. India 14.4.1.2. Thailand 14.4.1.3. Indonesia 14.4.1.4. Malaysia 14.4.1.5. Rest of South Asia & ASEAN 14.4.2. By Drug Class 14.4.3. By Indication 14.4.4. By Route of Administration 14.4.5. By Distribution Channel 15. Oceania Oncology Small Molecule Drugs Market Analysis and Forecast 15.1. Introduction / Key Findings 15.2. Pricing Analysis 15.3. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2017-2021 15.4. Market Size (US$ Billion) Forecast By Market Taxonomy, 2022 - 2032 15.4.1. By Country 15.4.1.1. Australia 15.4.1.2. New Zealand 15.4.2. Rest of South Asia & Oceania 15.4.3. By Drug Class 15.4.4. By Indication 15.4.5. By Route of Administration 15.4.6. By Distribution Channel 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Drug Class 15.5.3. By Indication 15.5.4. By Route of Administration 15.5.5. By Distribution Channel 16. Middle East & Africa Oncology Small Molecule Drugs Market Analysis and Forecast 16.1. Introduction / Key Findings 16.2. Pricing Analysis 16.3. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2017-2021 16.4. Market Size (US$ Billion) Forecast By Market Taxonomy, 2022 - 2032 16.4.1. By Country 16.4.1.1. GCC Countries 16.4.1.2. South Africa 16.4.1.3. Northern Africa 16.4.1.4. Turkey 16.4.1.5. Rest of Middle East & Africa 16.4.2. By Drug Class 16.4.3. By Indication 16.4.4. By Route of Administration 16.4.5. By Distribution Channel 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Drug Class 16.5.3. By Indication 16.5.4. By Route of Administration 16.5.5. By Distribution Channel 17. Country-level Oncology Small Molecule Drugs Market Analysis and Forecast 17.1. Introduction / Key Findings 17.1.1. Market Value Proportion Analysis, By Key Countries 17.1.2. Global Vs. Country Growth Comparison 17.2. US Oncology Small Molecule Drugs Market Analysis 17.2.1. Value Proportion Analysis by Market Taxonomy 17.2.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.2.2.1. By Drug Class 17.2.2.2. By Indication 17.2.2.3. By Route of Administration 17.2.2.4. By Distribution Channel 17.3. Canada Oncology Small Molecule Drugs Market Analysis 17.3.1. Value Proportion Analysis by Market Taxonomy 17.3.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.3.2.1. By Drug Class 17.3.2.2. By Indication 17.3.2.3. By Route of Administration 17.3.2.4. By Distribution Channel 17.4. Brazil Oncology Small Molecule Drugs Market Analysis 17.4.1. Value Proportion Analysis by Market Taxonomy 17.4.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.4.2.1. By Drug Class 17.4.2.2. By Indication 17.4.2.3. By Route of Administration 17.4.2.4. By Distribution Channel 17.5. Mexico Oncology Small Molecule Drugs Market Analysis 17.5.1. Value Proportion Analysis by Market Taxonomy 17.5.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.5.2.1. By Drug Class 17.5.2.2. By Indication 17.5.2.3. By Route of Administration 17.5.2.4. By Distribution Channel 17.6. Argentina Oncology Small Molecule Drugs Market Analysis 17.6.1. Value Proportion Analysis by Market Taxonomy 17.6.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.6.2.1. By Drug Class 17.6.2.2. By Indication 17.6.2.3. By Route of Administration 17.6.2.4. By Distribution Channel 17.7. Germany Oncology Small Molecule Drugs Market Analysis 17.7.1. Value Proportion Analysis by Market Taxonomy 17.7.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.7.2.1. By Drug Class 17.7.2.2. By Indication 17.7.2.3. By Route of Administration 17.7.2.4. By Distribution Channel 17.8. France Oncology Small Molecule Drugs Market Analysis 17.8.1. Value Proportion Analysis by Market Taxonomy 17.8.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.8.2.1. By Drug Class 17.8.2.2. By Indication 17.8.2.3. By Route of Administration 17.8.2.4. By Distribution Channel 17.9. Italy Oncology Small Molecule Drugs Market Analysis 17.9.1. Value Proportion Analysis by Market Taxonomy 17.9.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.9.2.1. By Drug Class 17.9.2.2. By Indication 17.9.2.3. By Route of Administration 17.9.2.4. By Distribution Channel 17.10. Spain Oncology Small Molecule Drugs Market Analysis 17.10.1. Value Proportion Analysis by Market Taxonomy 17.10.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.10.2.1. By Drug Class 17.10.2.2. By Indication 17.10.2.3. By Route of Administration 17.10.2.4. By Distribution Channel 17.11. BENELUX Oncology Small Molecule Drugs Market Analysis 17.11.1. Value Proportion Analysis by Market Taxonomy 17.11.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.11.2.1. By Drug Class 17.11.2.2. By Indication 17.11.2.3. By Route of Administration 17.11.2.4. By Distribution Channel 17.12. Russia Oncology Small Molecule Drugs Market Analysis 17.12.1. Value Proportion Analysis by Market Taxonomy 17.12.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.12.2.1. By Drug Class 17.12.2.2. By Indication 17.12.2.3. By Route of Administration 17.12.2.4. By Distribution Channel 17.13. U.K. Oncology Small Molecule Drugs Market Analysis 17.13.1. Value Proportion Analysis by Market Taxonomy 17.13.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.13.2.1. By Drug Class 17.13.2.2. By Indication 17.13.2.3. By Route of Administration 17.13.2.4. By Distribution Channel 17.14. China Oncology Small Molecule Drugs Market Analysis 17.14.1. Value Proportion Analysis by Market Taxonomy 17.14.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.14.2.1. By Drug Class 17.14.2.2. By Indication 17.14.2.3. By Route of Administration 17.14.2.4. By Distribution Channel 17.15. Japan Oncology Small Molecule Drugs Market Analysis 17.15.1. Value Proportion Analysis by Market Taxonomy 17.15.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.15.2.1. By Drug Class 17.15.2.2. By Indication 17.15.2.3. By Route of Administration 17.15.2.4. By Distribution Channel 17.16. South Korea Oncology Small Molecule Drugs Market Analysis 17.16.1. Value Proportion Analysis by Market Taxonomy 17.16.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.16.2.1. By Drug Class 17.16.2.2. By Indication 17.16.2.3. By Route of Administration 17.16.2.4. By Distribution Channel 17.17. India Oncology Small Molecule Drugs Market Analysis 17.17.1. Value Proportion Analysis by Market Taxonomy 17.17.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.17.2.1. By Drug Class 17.17.2.2. By Indication 17.17.2.3. By Route of Administration 17.17.2.4. By Distribution Channel 17.18. Thailand Oncology Small Molecule Drugs Market Analysis 17.18.1. Value Proportion Analysis by Market Taxonomy 17.18.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.18.2.1. By Drug Class 17.18.2.2. By Indication 17.18.2.3. By Route of Administration 17.18.2.4. By Distribution Channel 17.19. Indonesia Oncology Small Molecule Drugs Market Analysis 17.19.1. Value Proportion Analysis by Market Taxonomy 17.19.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.19.2.1. By Drug Class 17.19.2.2. By Indication 17.19.2.3. By Route of Administration 17.19.2.4. By Distribution Channel 17.20. Malaysia Oncology Small Molecule Drugs Market Analysis 17.20.1. Value Proportion Analysis by Market Taxonomy 17.20.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.20.2.1. By Drug Class 17.20.2.2. By Indication 17.20.2.3. By Route of Administration 17.20.2.4. By Distribution Channel 17.21. Rest of South Asia & ASEAN Countries Oncology Small Molecule Drugs Market Analysis 17.21.1. Value Proportion Analysis by Market Taxonomy 17.21.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.21.2.1. By Drug Class 17.21.2.2. By Indication 17.21.2.3. By Route of Administration 17.21.2.4. By Distribution Channel 17.22. Australia Oncology Small Molecule Drugs Market Analysis 17.22.1. Value Proportion Analysis by Market Taxonomy 17.22.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.22.2.1. By Drug Class 17.22.2.2. By Indication 17.22.2.3. By Route of Administration 17.22.2.4. By Distribution Channel 17.23. New Zealand Oncology Small Molecule Drugs Market Analysis 17.23.1. Value Proportion Analysis by Market Taxonomy 17.23.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.23.2.1. By Drug Class 17.23.2.2. By Indication 17.23.2.3. By Route of Administration 17.23.2.4. By Distribution Channel 17.24. GCC Countries Oncology Small Molecule Drugs Market Analysis 17.24.1. Value Proportion Analysis by Market Taxonomy 17.24.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.24.2.1. By Drug Class 17.24.2.2. By Indication 17.24.2.3. By Route of Administration 17.24.2.4. By Distribution Channel 17.25. Turkey Oncology Small Molecule Drugs Market Analysis 17.25.1. Value Proportion Analysis by Market Taxonomy 17.25.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.25.2.1. By Drug Class 17.25.2.2. By Indication 17.25.2.3. By Route of Administration 17.25.2.4. By Distribution Channel 17.26. Northern Africa Oncology Small Molecule Drugs Market Analysis 17.26.1. Value Proportion Analysis by Market Taxonomy 17.26.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.26.2.1. By Drug Class 17.26.2.2. By Indication 17.26.2.3. By Route of Administration 17.26.2.4. By Distribution Channel 17.27. South Africa Oncology Small Molecule Drugs Market Analysis 17.27.1. Value Proportion Analysis by Market Taxonomy 17.27.2. Value (US$ Billion) Analysis and Forecast by Market Taxonomy, 2017-2032 17.27.2.1. By Drug Class 17.27.2.2. By Indication 17.27.2.3. By Route of Administration 17.27.2.4. By Distribution Channel 18. Oncology Small Molecule Drugs Market Structure Analysis 18.1. Market Analysis by Tier of Companies 18.2. Market Concentration of Players 18.3. Market Share Analysis of Top Players 18.4. Market Presence Analysis 19. Oncology Small Molecule Drugs Competition Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking of Products 19.3. Competition Deep Dive: Oncology Small Molecule Drugs 19.3.1. Novartis AG 19.3.1.1. Overview 19.3.1.2. Product Portfolio 19.3.1.3. Key Financials 19.3.1.4. Distribution Channel Footprint 19.3.1.5. SWOT Analysis 19.3.1.6. Key Developments 19.3.1.7. Strategy Overview 19.3.2. Pfizer Inc. 19.3.2.1. Overview 19.3.2.2. Product Portfolio 19.3.2.3. Key Financials 19.3.2.4. Distribution Channel Footprint 19.3.2.5. SWOT Analysis 19.3.2.6. Key Developments 19.3.2.7. Strategy Overview 19.3.3. Amgen Plc. 19.3.3.1. Overview 19.3.3.2. Product Portfolio 19.3.3.3. Key Financials 19.3.3.4. Distribution Channel Footprint 19.3.3.5. SWOT Analysis 19.3.3.6. Key Developments 19.3.3.7. Strategy Overview 19.3.4. F. Hoffmann-La Roche Ltd. 19.3.4.1. Overview 19.3.4.2. Product Portfolio 19.3.4.3. Key Financials 19.3.4.4. Distribution Channel Footprint 19.3.4.5. SWOT Analysis 19.3.4.6. Key Developments 19.3.4.7. Strategy Overview 19.3.5. Eli Lilly and Company 19.3.5.1. Overview 19.3.5.2. Product Portfolio 19.3.5.3. Key Financials 19.3.5.4. Distribution Channel Footprint 19.3.5.5. SWOT Analysis 19.3.5.6. Key Developments 19.3.5.7. Strategy Overview 19.3.6. Sanofi SA 19.3.6.1. Overview 19.3.6.2. Product Portfolio 19.3.6.3. Key Financials 19.3.6.4. Distribution Channel Footprint 19.3.6.5. SWOT Analysis 19.3.6.6. Key Developments 19.3.6.7. Strategy Overview 19.3.7. Bristol-Myers Squibb Company 19.3.7.1. Overview 19.3.7.2. Product Portfolio 19.3.7.3. Key Financials 19.3.7.4. Distribution Channel Footprint 19.3.7.5. SWOT Analysis 19.3.7.6. Key Developments 19.3.7.7. Strategy Overview 19.3.8. AbbVie Inc. 19.3.8.1. Overview 19.3.8.2. Product Portfolio 19.3.8.3. Key Financials 19.3.8.4. Distribution Channel Footprint 19.3.8.5. SWOT Analysis 19.3.8.6. Key Developments 19.3.8.7. Strategy Overview 19.3.9. Bayer AG 19.3.9.1. Overview 19.3.9.2. Product Portfolio 19.3.9.3. Key Financials 19.3.9.4. Distribution Channel Footprint 19.3.9.5. SWOT Analysis 19.3.9.6. Key Developments 19.3.9.7. Strategy Overview 19.3.10. Incyte Corporation 19.3.10.1. Overview 19.3.10.2. Product Portfolio 19.3.10.3. Key Financials 19.3.10.4. Distribution Channel Footprint 19.3.10.5. SWOT Analysis 19.3.10.6. Key Developments 19.3.10.7. Strategy Overview 19.3.11. Celgene Corporation 19.3.11.1. Overview 19.3.11.2. Product Portfolio 19.3.11.3. Key Financials 19.3.11.4. Distribution Channel Footprint 19.3.11.5. SWOT Analysis 19.3.11.6. Key Developments 19.3.11.7. Strategy Overview 19.3.12. AstraZeneca Plc. 19.3.12.1. Overview 19.3.12.2. Product Portfolio 19.3.12.3. Key Financials 19.3.12.4. Distribution Channel Footprint 19.3.12.5. SWOT Analysis 19.3.12.6. Key Developments 19.3.12.7. Strategy Overview 19.3.13. Exelixis Inc. 19.3.13.1. Overview 19.3.13.2. Product Portfolio 19.3.13.3. Key Financials 19.3.13.4. Distribution Channel Footprint 19.3.13.5. SWOT Analysis 19.3.13.6. Key Developments 19.3.13.7. Strategy Overview 19.3.14. Millennium Pharmaceuticals Inc. (Takeda) 19.3.14.1. Overview 19.3.14.2. Product Portfolio 19.3.14.3. Key Financials 19.3.14.4. Distribution Channel Footprint 19.3.14.5. SWOT Analysis 19.3.14.6. Key Developments 19.3.14.7. Strategy Overview 20. Assumptions & Acronyms Used 21. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Region, 2017-2021
Table 02: Global Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Region, 2022-2032
Table 03: Global Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Drug Class, 2017-2021
Table 04: Global Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Drug Class, 2022-2032
Table 05: Global Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Indication, 2017-2021
Table 06: Global Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Indication, 2022-2032
Table 07: Global Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Route of Administration, 2017-2021
Table 08: Global Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Route of Administration, 2022-2032
Table 09: Global Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Distribution Channel, 2017-2021
Table 10: Global Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Distribution Channel, 2022-2032
Table 11: North America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Country, 2017-2021
Table 12: North America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Country, 2022-2032
Table 13: North America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Drug Class, 2017-2021
Table 14: North America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Drug Class, 2022-2032
Table 15: North America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Indication, 2017-2021
Table 16: North America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Indication, 2022-2032
Table 17: North America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Route of Administration, 2017-2021
Table 18: North America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Route of Administration, 2022-2032
Table 19: North America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Distribution Channel, 2017-2021
Table 20: North America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Distribution Channel, 2022-2032
Table 21: Latin America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Country, 2017-2021
Table 22: Latin America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Country, 2022-2032
Table 23: Latin America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Drug Class, 2017-2021
Table 24: Latin America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Drug Class, 2022-2032
Table 25: Latin America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Indication, 2017-2021
Table 26: Latin America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Indication, 2022-2032
Table 27: Latin America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Route of Administration, 2017-2021
Table 28: Latin America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Route of Administration, 2022-2032
Table 29: Latin America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Distribution Channel, 2017-2021
Table 30: Latin America Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Distribution Channel, 2022-2032
Table 31: Europe Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Country, 2017-2021
Table 32: Europe Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Country, 2022-2032
Table 33: Europe Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Drug Class, 2017-2021
Table 34: Europe Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Drug Class, 2022-2032
Table 35: Europe Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Indication, 2017-2021
Table 36: Europe Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Indication, 2022-2032
Table 37: Europe Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Route of Administration, 2017-2021
Table 38: Europe Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Route of Administration, 2022-2032
Table 39: Europe Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Distribution Channel, 2017-2021
Table 40: Europe Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Distribution Channel, 2022-2032
Table 41: East Asia Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Country, 2017-2021
Table 42: East Asia Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Country, 2022-2032
Table 43: East Asia Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Drug Class, 2017-2021
Table 44: East Asia Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Drug Class, 2022-2032
Table 45: East Asia Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Indication, 2017-2021
Table 46: East Asia Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Indication, 2022-2032
Table 47: East Asia Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Route of Administration, 2017-2021
Table 48: East Asia Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Route of Administration, 2022-2032
Table 49: East Asia Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Distribution Channel, 2017-2021
Table 50: East Asia Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Distribution Channel, 2022-2032
Table 51: South Asia & ASEAN Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Country, 2017-2021
Table 52: South Asia & ASEAN Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Country, 2022-2032
Table 53: South Asia & ASEAN Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Drug Class, 2017-2021
Table 54: South Asia & ASEAN Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Drug Class, 2022-2032
Table 55: South Asia & ASEAN Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Indication, 2017-2021
Table 56: South Asia & ASEAN Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Indication, 2022-2032
Table 57: South Asia & ASEAN Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Route of Administration, 2017-2021
Table 58: South Asia & ASEAN Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Route of Administration, 2022-2032
Table 59: South Asia & ASEAN Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Distribution Channel, 2017-2021
Table 60: South Asia & ASEAN Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Distribution Channel, 2022-2032
Table 61: Oceania Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Country, 2017-2021
Table 62: Oceania Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Country, 2022-2032
Table 63: Oceania Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Drug Class, 2017-2021
Table 64: Oceania Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Drug Class, 2022-2032
Table 65: Oceania Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Indication, 2017-2021
Table 66: Oceania Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Indication, 2022-2032
Table 67: Oceania Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Route of Administration, 2017-2021
Table 68: Oceania Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Route of Administration, 2022-2032
Table 69: Oceania Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Distribution Channel, 2017-2021
Table 70: Oceania Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Distribution Channel, 2022-2032
Table 71: MEA Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Country, 2017-2021
Table 72: MEA Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Country, 2022-2032
Table 73: MEA Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Drug Class, 2017-2021
Table 74: MEA Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Drug Class, 2022-2032
Table 75: MEA Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Indication, 2017-2021
Table 76: MEA Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Indication, 2022-2032
Table 77: MEA Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Route of Administration, 2017-2021
Table 78: MEA Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Route of Administration, 2022-2032
Table 79: MEA Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Distribution Channel, 2017-2021
Table 80: MEA Oncology Small Molecule Drugs Market Value (USD Billion) and Forecast by Distribution Channel, 2022-2032
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Oncology Small Molecule Drugs Market Value (USD Billion) Forecast, 2022-2032
Figure 02: Global Oncology Small Molecule Drugs Market Absolute $ Opportunity (USD Billion), 2022-2032
Figure 03: Global Oncology Small Molecule Drugs Market Value (USD Billion) by Region, 2022 & 2032
Figure 04: Global Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Region, 2022-2032
Figure 05: Global Oncology Small Molecule Drugs Market Value (USD Billion) by Drug Class, 2022 & 2032
Figure 06: Global Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Drug Class, 2022-2032
Figure 07: Global Oncology Small Molecule Drugs Market Value (USD Billion) by Indication, 2022 & 2032
Figure 08: Global Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Indication, 2022-2032
Figure 09: Global Oncology Small Molecule Drugs Market Value (USD Billion) by Route of Administration, 2022 & 2032
Figure 10: Global Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Route of Administration, 2022-2032
Figure 11: Global Oncology Small Molecule Drugs Market Value (USD Billion) by Distribution Channel, 2022 & 2032
Figure 12: Global Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Distribution Channel, 2022-2032
Figure 13: North America Oncology Small Molecule Drugs Market Value (USD Billion) Forecast, 2022-2032
Figure 14: North America Oncology Small Molecule Drugs Market Absolute $ Opportunity (USD Billion), 2022-2032
Figure 15: North America Oncology Small Molecule Drugs Market Value (USD Billion) by Country, 2022 & 2032
Figure 16: North America Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Country, 2022-2032
Figure 17: North America Oncology Small Molecule Drugs Market Value (USD Billion) by Drug Class, 2022 & 2032
Figure 18: North America Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Drug Class, 2022-2032
Figure 19: North America Oncology Small Molecule Drugs Market Value (USD Billion) by Indication, 2022 & 2032
Figure 20: North America Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Indication, 2022-2032
Figure 21: North America Oncology Small Molecule Drugs Market Value (USD Billion) by Route of Administration, 2022 & 2032
Figure 22: North America Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Route of Administration, 2022-2032
Figure 23: North America Oncology Small Molecule Drugs Market Value (USD Billion) by Distribution Channel, 2022 & 2032
Figure 24: North America Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Distribution Channel, 2022-2032
Figure 25: North America Oncology Small Molecule Drugs Market Attractiveness Analysis by Country, 2022-2032
Figure 26: North America Oncology Small Molecule Drugs Market Attractiveness Analysis by Drug Class, 2022-2032
Figure 27: North America Oncology Small Molecule Drugs Market Attractiveness Analysis by Indication, 2022-2032
Figure 28: North America Oncology Small Molecule Drugs Market Attractiveness Analysis by Route of Administration, 2022-2032
Figure 29: North America Oncology Small Molecule Drugs Market Attractiveness Analysis by Distribution Channel, 2022-2032
Figure 30: Latin America Oncology Small Molecule Drugs Market Value (USD Billion) Forecast, 2022-2032
Figure 31: Latin America Oncology Small Molecule Drugs Market Absolute $ Opportunity (USD Billion), 2022-2032
Figure 32: Latin America Oncology Small Molecule Drugs Market Value (USD Billion) by Country, 2022 & 2032
Figure 33: Latin America Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Country, 2022-2032
Figure 34: Latin America Oncology Small Molecule Drugs Market Value (USD Billion) by Drug Class, 2022 & 2032
Figure 35: Latin America Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Drug Class, 2022-2032
Figure 36: Latin America Oncology Small Molecule Drugs Market Value (USD Billion) by Indication, 2022 & 2032
Figure 37: Latin America Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Indication, 2022-2032
Figure 38: Latin America Oncology Small Molecule Drugs Market Value (USD Billion) by Route of Administration, 2022 & 2032
Figure 39: Latin America Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Route of Administration, 2022-2032
Figure 40: Latin America Oncology Small Molecule Drugs Market Value (USD Billion) by Distribution Channel, 2022 & 2032
Figure 41: Latin America Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Distribution Channel, 2022-2032
Figure 42: Latin America Oncology Small Molecule Drugs Market Attractiveness Analysis by Country, 2022-2032
Figure 43: Latin America Oncology Small Molecule Drugs Market Attractiveness Analysis by Drug Class, 2022-2032
Figure 44: Latin America Oncology Small Molecule Drugs Market Attractiveness Analysis by Indication, 2022-2032
Figure 45: Latin America Oncology Small Molecule Drugs Market Attractiveness Analysis by Route of Administration, 2022-2032
Figure 46: Latin America Oncology Small Molecule Drugs Market Attractiveness Analysis by Distribution Channel, 2022-2032
Figure 47: Europe Oncology Small Molecule Drugs Market Value (USD Billion) Forecast, 2022-2032
Figure 48: Europe Oncology Small Molecule Drugs Market Absolute $ Opportunity (USD Billion), 2022-2032
Figure 49: Europe Oncology Small Molecule Drugs Market Value (USD Billion) by Country, 2022 & 2032
Figure 50: Europe Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Country, 2022-2032
Figure 51: Europe Oncology Small Molecule Drugs Market Value (USD Billion) by Drug Class, 2022 & 2032
Figure 52: Europe Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Drug Class, 2022-2032
Figure 53: Europe Oncology Small Molecule Drugs Market Value (USD Billion) by Indication, 2022 & 2032
Figure 54: Europe Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Indication, 2022-2032
Figure 55: Europe Oncology Small Molecule Drugs Market Value (USD Billion) by Route of Administration, 2022 & 2032
Figure 56: Europe Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Route of Administration, 2022-2032
Figure 57: Europe Oncology Small Molecule Drugs Market Value (USD Billion) by Distribution Channel, 2022 & 2032
Figure 58: Europe Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Distribution Channel, 2022-2032
Figure 59: Europe Oncology Small Molecule Drugs Market Attractiveness Analysis by Country, 2022-2032
Figure 60: Europe Oncology Small Molecule Drugs Market Attractiveness Analysis by Drug Class, 2022-2032
Figure 61: Europe Oncology Small Molecule Drugs Market Attractiveness Analysis by Indication, 2022-2032
Figure 62: Europe Oncology Small Molecule Drugs Market Attractiveness Analysis by Route of Administration, 2022-2032
Figure 63: Europe Oncology Small Molecule Drugs Market Attractiveness Analysis by Distribution Channel, 2022-2032
Figure 64: East Asia Oncology Small Molecule Drugs Market Value (USD Billion) Forecast, 2022-2032
Figure 65: East Asia Oncology Small Molecule Drugs Market Absolute $ Opportunity (USD Billion), 2022-2032
Figure 66: East Asia Oncology Small Molecule Drugs Market Value (USD Billion) by Country, 2022 & 2032
Figure 67: East Asia Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Country, 2022-2032
Figure 68: East Asia Oncology Small Molecule Drugs Market Value (USD Billion) by Drug Class, 2022 & 2032
Figure 69: East Asia Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Drug Class, 2022-2032
Figure 70: East Asia Oncology Small Molecule Drugs Market Value (USD Billion) by Indication, 2022 & 2032
Figure 71: East Asia Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Indication, 2022-2032
Figure 72: East Asia Oncology Small Molecule Drugs Market Value (USD Billion) by Route of Administration, 2022 & 2032
Figure 73: East Asia Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Route of Administration, 2022-2032
Figure 74: East Asia Oncology Small Molecule Drugs Market Value (USD Billion) by Distribution Channel, 2022 & 2032
Figure 75: East Asia Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Distribution Channel, 2022-2032
Figure 76: East Asia Oncology Small Molecule Drugs Market Attractiveness Analysis by Country, 2022-2032
Figure 77: East Asia Oncology Small Molecule Drugs Market Attractiveness Analysis by Drug Class, 2022-2032
Figure 78: East Asia Oncology Small Molecule Drugs Market Attractiveness Analysis by Indication, 2022-2032
Figure 79: East Asia Oncology Small Molecule Drugs Market Attractiveness Analysis by Route of Administration, 2022-2032
Figure 80: East Asia Oncology Small Molecule Drugs Market Attractiveness Analysis by Distribution Channel, 2022-2032
Figure 81: South Asia & ASEAN Oncology Small Molecule Drugs Market Value (USD Billion) Forecast, 2022-2032
Figure 82: South Asia & ASEAN Oncology Small Molecule Drugs Market Absolute $ Opportunity (USD Billion), 2022-2032
Figure 83: South Asia & ASEAN Oncology Small Molecule Drugs Market Value (USD Billion) by Country, 2022 & 2032
Figure 84: South Asia & ASEAN Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Country, 2022-2032
Figure 85: South Asia & ASEAN Oncology Small Molecule Drugs Market Value (USD Billion) by Drug Class, 2022 & 2032
Figure 86: South Asia & ASEAN Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Drug Class, 2022-2032
Figure 87: South Asia & ASEAN Oncology Small Molecule Drugs Market Value (USD Billion) by Indication, 2022 & 2032
Figure 88: South Asia & ASEAN Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Indication, 2022-2032
Figure 89: South Asia & ASEAN Oncology Small Molecule Drugs Market Value (USD Billion) by Route of Administration, 2022 & 2032
Figure 90: South Asia & ASEAN Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Route of Administration, 2022-2032
Figure 91: South Asia & ASEAN Oncology Small Molecule Drugs Market Value (USD Billion) by Distribution Channel, 2022 & 2032
Figure 92: South Asia & ASEAN Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Distribution Channel, 2022-2032
Figure 93: South Asia & ASEAN Oncology Small Molecule Drugs Market Attractiveness Analysis by Country, 2022-2032
Figure 94: South Asia & ASEAN Oncology Small Molecule Drugs Market Attractiveness Analysis by Drug Class, 2022-2032
Figure 95: South Asia & ASEAN Oncology Small Molecule Drugs Market Attractiveness Analysis by Indication, 2022-2032
Figure 96: South Asia & ASEAN Oncology Small Molecule Drugs Market Attractiveness Analysis by Route of Administration, 2022-2032
Figure 97: South Asia & ASEAN Oncology Small Molecule Drugs Market Attractiveness Analysis by Distribution Channel, 2022-2032
Figure 98: Oceania Oncology Small Molecule Drugs Market Value (USD Billion) Forecast, 2022-2032
Figure 99: Oceania Oncology Small Molecule Drugs Market Absolute $ Opportunity (USD Billion), 2022-2032
Figure 100: Oceania Oncology Small Molecule Drugs Market Value (USD Billion) by Country, 2022 & 2032
Figure 101: Oceania Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Country, 2022-2032
Figure 102: Oceania Oncology Small Molecule Drugs Market Value (USD Billion) by Drug Class, 2022 & 2032
Figure 103: Oceania Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Drug Class, 2022-2032
Figure 104: Oceania Oncology Small Molecule Drugs Market Value (USD Billion) by Indication, 2022 & 2032
Figure 105: Oceania Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Indication, 2022-2032
Figure 106: Oceania Oncology Small Molecule Drugs Market Value (USD Billion) by Route of Administration, 2022 & 2032
Figure 107: Oceania Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Route of Administration, 2022-2032
Figure 108: Oceania Oncology Small Molecule Drugs Market Value (USD Billion) by Distribution Channel, 2022 & 2032
Figure 109: Oceania Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Distribution Channel, 2022-2032
Figure 110: Oceania Oncology Small Molecule Drugs Market Attractiveness Analysis by Country, 2022-2032
Figure 111: Oceania Oncology Small Molecule Drugs Market Attractiveness Analysis by Drug Class, 2022-2032
Figure 112: Oceania Oncology Small Molecule Drugs Market Attractiveness Analysis by Indication, 2022-2032
Figure 113: Oceania Oncology Small Molecule Drugs Market Attractiveness Analysis by Route of Administration, 2022-2032
Figure 114: Oceania Oncology Small Molecule Drugs Market Attractiveness Analysis by Distribution Channel, 2022-2032
Figure 115: MEA Oncology Small Molecule Drugs Market Value (USD Billion) Forecast, 2022-2032
Figure 116: MEA Oncology Small Molecule Drugs Market Absolute $ Opportunity (USD Billion), 2022-2032
Figure 117: MEA Oncology Small Molecule Drugs Market Value (USD Billion) by Country, 2022 & 2032
Figure 118: MEA Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Country, 2022-2032
Figure 119: MEA Oncology Small Molecule Drugs Market Value (USD Billion) by Drug Class, 2022 & 2032
Figure 120: MEA Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Drug Class, 2022-2032
Figure 121: MEA Oncology Small Molecule Drugs Market Value (USD Billion) by Indication, 2022 & 2032
Figure 122: MEA Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Indication, 2022-2032
Figure 123: MEA Oncology Small Molecule Drugs Market Value (USD Billion) by Route of Administration, 2022 & 2032
Figure 124: MEA Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Route of Administration, 2022-2032
Figure 125: MEA Oncology Small Molecule Drugs Market Value (USD Billion) by Distribution Channel, 2022 & 2032
Figure 126: MEA Oncology Small Molecule Drugs Market Y-o-Y Growth Rate by Distribution Channel, 2022-2032
Figure 127: MEA Oncology Small Molecule Drugs Market Attractiveness Analysis by Country, 2022-2032
Figure 128: MEA Oncology Small Molecule Drugs Market Attractiveness Analysis by Drug Class, 2022-2032
Figure 129: MEA Oncology Small Molecule Drugs Market Attractiveness Analysis by Indication, 2022-2032
Figure 130: MEA Oncology Small Molecule Drugs Market Attractiveness Analysis by Route of Administration, 2022-2032
Figure 131: MEA Oncology Small Molecule Drugs Market Attractiveness Analysis by Distribution Channel, 2022-2032
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
Which segment accounts for the highest revenue generation?
Targeted therapy drugs account for 50.8% share, the highest in the global market.
How is the market anticipated to perform over the decade?
Sales of oncology small molecule drugs are anticipated to increase at 5.5% CAGR and reach US$ 135.4 billion by 2032.
What is the revenue of the oncology small molecule drugs market?
The global oncology small molecule drugs market is valued at US$ 79 billion in 2022.
Which regional market is being eyed by most manufacturers?
North America tops the global oncology small molecule drugs market accounting for 48.2% market share in 2021.
How did the market perform over the past few years?
From 2017 to 2021, consumption of oncology small molecule drugs increased at 5.4% CAGR.
Oncology Small Molecule Drugs Market